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Context: Brain white matter hyperintensities are seen on routine clinical imaging in 46% of adults
with congenital adrenal hyperplasia (CAH). The extent and functional relevance of these abnor-
malities have not been studied with quantitative magnetic resonance imaging (MRI) analysis.
Objective: To examine white matter microstructure, neural volumes, and central nervous system
(CNS) metabolites in CAH due to 21-hydroxylase deficiency (21OHD) and to determine whether
identified abnormalities are associated with cognition, glucocorticoid, and androgen exposure.
Design, Setting, and Participants: A cross-sectional study at a tertiary hospital including 19 women
(18 to 50 years) with 21OHD and 19 age-matched healthy women.
Main Outcome Measure: Recruits underwent cognitive assessment and brain imaging, including
diffusion weighted imaging of white matter, T1-weighted volumetry, and magnetic resonance
spectroscopy for neural metabolites. We evaluated white matter microstructure by using tract-
based spatial statistics. We compared cognitive scores, neural volumes, and metabolites between
groups and relationships between glucocorticoid exposure, MRI, and neurologic outcomes.
Results: Patients with 21OHD had widespread reductions in white matter structural integrity, re-
duced volumes of right hippocampus, bilateral thalami, cerebellum, and brainstem, and reduced
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mesial temporal lobe total choline content. Working memory, processing speed, and digit span and
matrix reasoning scores were reduced in patients with 21OHD, despite similar education and in-
telligence to controls. Patients with 21OHD exposed to higher glucocorticoid doses had greater
abnormalities in white matter microstructure and cognitive performance.
Conclusion:We demonstrate that 21OHD and current glucocorticoid replacement regimens have a
profound impact on brainmorphology and function. If reversible, these CNSmarkers are a potential
target for treatment. (J Clin Endocrinol Metab 103: 1330–1341, 2018)
Steroid hormones regulate central nervous system(CNS) development, exerting trophic effects on cell
survival, differentiation, maturation, and synaptogenesis
(1, 2). The most common variant of the inborn ste-
roidogenic disorder congenital adrenal hyperplasia (CAH),
21-hydroxylase deficiency (21OHD), disrupts adrenal
steroidogenesis at critical branch points of glucocorticoid
(cortisol) and mineralocorticoid (aldosterone) synthesis.
Reduced glucocorticoid feedback to the hypothalamo-
pituitary axis results in increased central stimulation of
adrenal steroidogenesis. This leads to increased adrenal
androgen production and subsequent systemic androgen
excess, glucocorticoid deficiency, and, in two-thirds of
patients, clinically apparent mineralocorticoid deficiency
(3). Medical treatment aims to replace the deficient
hormones and to limit exposure to androgen excess.
However, in clinical practice, patients are often exposed
to both glucocorticoid and androgen excess (3). CAH
therefore provides a pathophysiological model suited
to study the impact of fluctuations in glucocorticoid
and androgen exposure on human brain structure
and function.
Qualitative evaluation of structural T2-weighted
magnetic resonance imaging (MRI) studies in patients
with CAH provides evidence of white matter hyper-
intensities (leukoaraiosis) in #46% of patients (4, 5),
located predominantly in the temporal lobe, amygdala,
hippocampus, periventricular matter, and corpus cal-
losum. Leukoaraiosis is an uncommon incidental finding
in healthy adults aged ,45 years (6). The pathophysi-
ology of leukoaraiosis remains poorly defined (7);
however, the presence of local whitematter abnormalities
appears to indicate a global dysregulation of whitematter
structure, with changes in white matter microstructure in
affected patients not limited to the areas of abnormality
identified on visual inspection (8). Diffusion weighted
imaging, a noninvasive MRI technique, provides quan-
titative indices of brain development, enabling the in vivo
examination of white matter microstructure and char-
acterization of white matter anatomy, including the de-
gree of connectivity between different regions of the brain
(9, 10). In pathologic conditions, diffusion anisotropy of
water molecules is reduced because of altered diffusivity
and disorganization of the white matter fibers. These
measurements may become abnormal even before the
lesion is morphologically apparent on conventional
MRIs, helping both with early detection and with de-
fining the extent of lesions. We hypothesized that dif-
fusion tensor imaging (DTI) would identify significant
reductions in quantitative indices of white matter mi-
crostructure in patients with CAH, including mean dif-
fusivity, which reflects the degree of water mobility, and
fractional anisotropy (FA), which is affected by axonal
caliber, fiber density, and degree of myelination (11).
Measurements of in vivo human brain volumes can
provide insights into the pathophysiology of patients’
cognitive abnormalities, with neuroimaging increasingly
used in clinical trials as a biomarker to study the impact of
treatment modifications. The extent of volumetric ab-
normalities present in patients with CAH has not pre-
viously been investigated with high-resolution MRI in
conjunction with automated quantitative data analysis.
In view of the high concentrations of androgen, miner-
alocorticoid, and glucocorticoid receptors in the hippo-
campus, amygdala, thalamus, brainstem, and cerebellum
(2, 12–14), we hypothesized that patients with CAH
would have localized volume loss in these regions.
Magnetic resonance spectroscopy (MRS), which en-
ables the in vivo measurement of cerebral metabolites,
provides a sensitive tool tomeasure the impact of changes
in steroid hormone exposure on the brain. It has pre-
viously been used to investigate how excess glucocorti-
coid exposure affects cerebral metabolite concentrations
in patients with Cushing disease (15). Patients with
Cushing syndrome have reduced total choline, with
normalization of the brain metabolite ratios after reso-
lution of Cushing disease (15). MRS has not previously
been performed in patients with CAH, in whom we
hypothesized that total choline would be reduced.
Glucocorticoids exert an inverted U-shaped influence
on human cognition, particularly on acquiring and
consolidating memory (2), whereas androgens have an
overall beneficial effect on cognitive control, verbal
memory, and spatial cognition in humans (1, 13, 16).
Although previous studies in patients with CAH have
consistently identified impairments in short-term and
working memory performance, thought to relate to ex-
cess glucocorticoid exposure, the relationship between
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these cognitive abnormalities and changes in brain
structure has not previously been investigated (17). We
hypothesized that neural abnormalities would correlate
with cognitive performance and that increased gluco-
corticoid exposure would be associated with poorer
performance on neuropsychometric tests and reductions
in neural volumes, FA, and total choline.
Subjects and Methods
Patient selection
Adult women with CAH due to 21OHD diagnosed by
hormonal and genetic testing were recruited from the endocrine
clinic at University Hospital Birmingham and via the patient
support group Children Living With Inherited Metabolic Dis-
eases, Living With CAH. Local advertisements were placed
at University Hospital Birmingham National Health Service
Foundation Trust to recruit control subjects. Exclusion criteria
for both groups were pregnancy, hypothyroidism, a medical
condition known to affect cerebral anatomy, or metal in the
body. Additional exclusion criteria for the control group were
diagnosed psychiatric disorder, glucocorticoid use (ever), or
diagnosed learning disabilities. The study was approved by the
national research ethics committee of West Midlands, and all
participants gavewritten informed consent before participation.
Ethnicity, age at diagnosis, handedness, highest educational
level, employment category, and current glucocorticoid re-
placement dose were recorded. The genotype of patients with
21OHD was classified into genotype groups null, A, B, and C
(18). In patients taking prednisolone instead of hydrocortisone,
the equivalent dose was calculated by multiplying total pred-
nisolone dose by four (19). Educational status was graded 1 to
6 based on the participant’s highest level of educational
achievement [(1) Completed primary school; (2) Completed
middle school to age 16 years; (3)Completed high school to age
18 years; (4) Higher studies beyond school; (5) Degree; and (6)
Postgraduate degree]. All participants with CAH had fasting
9:00 to 11:00 AM blood samples taken on the day of MRI
acquisition before any medication for measurements of plasma
renin concentration, serum 17-hydroxyprogesterone, dehy-
droepiandrosterone, androstenedione, and testosterone liquid
chromatography and tandem mass spectrometry. Standing
height was measured with a stadiometer.
Psychometric assessment
Psychometric testing comprisingWechsler Adult Intelligence
Scale (WAIS) IV and Wechsler Memory Scale (WMS) IV as-
sessments was administered by a trained psychology research
assistant (20, 21).
Health-related quality of life and
mood questionnaires
All study participants completed the World Health Orga-
nization Quality of Life and Hospital Anxiety and Depression
Scale (HADS) questionnaires (22, 23). The World Health Or-
ganization Quality of Life questionnaire is an instrument to
assess general well-being and comprises 26 items to broadly
measure four domains: physical health, psychological health,
social relationships, and environment. The HADS is a 14-scale
questionnaire that is used to ascertain the levels of depression
and anxiety a subject is experiencing.
MRI acquisition
MRI was performed on a 3-T Philips Achieva scanner
with a 32-channel head coil. One neuroradiologist (V.S.)
blinded to the clinical data reviewed all images. DTI was
performed with a monopolar Stejskal–Tanner sequence over
61 directions, with a single b = 0 image and b-factor of
1500 s/mm2. Data were collected in the axial plane, with an
imaging matrix of 112 3 112 over 72 slices at an isotropic
resolution of 2 mm. An echo time of 78 ms was used with a
SENSE parallel imaging factor of 2. High-resolution three-
dimensional T1-weighted images were acquired (repetition
time = 8.40 ms, echo time = 3.8 ms, flip angle = 8°, field of view
= 288 mm, 175 slices, 2 mm isotropic voxels). MRS data were
acquired from an 18 3 18 3 18 mm voxel in the left mesial
temporal lobe and a 20 3 20 3 20 mm voxel in the right
parietal lobe. Point-resolved spectroscopy was performed at
3 T, with an echo time of 35 ms, a repetition time of 2000 ms,
and 128 repetitions. A water unsuppressed MRS was acquired
from the same voxel for water referencing.
Image analysis
Diffusion-weighted images were initially processed with the
Functional Magnetic Resonance Imaging of the Brain Software
Library (http://www.fmrib.ox.ac.uk/fsl). Data were inspected
for movement artifacts and then corrected for eddy current–
induced distortions. Brain extraction and calculation of diffu-
sion tensor FA and mean diffusivity maps were carried out
with Functional Magnetic Resonance Imaging of the Brain
Software Library tools. FA and mean diffusivity images were
processed with tract-based spatial statistics and automated,
observer-independent, voxel-by-voxel whole-brain between-
group analysis (corrected for age) (24). Initially, every FA
image was aligned to the FMRIB58 standard space FA map.
Second, the mean FA image across subjects was created. The
mean image was thinned and thresholded at a FA value of 0.2 to
create awhitematter tract skeleton representing the center of the
tracts common to all subjects. FA data projected onto these
skeletons was used in voxel-wise statistical comparisons with
the threshold-free cluster enhancement option (corrected for
multiple comparisons across space).
Amygdala, hippocampus, thalamus, cerebellum, brain-
stem, cerebrospinal fluid (CSF), and total brain volume were
determined from the T1-weighted MRI with FreeSurfer, an
automated segmentation tool (25). We selected the struc-
tures in the brain with the highest concentration of an-
drogen, mineralocorticoid, and glucocorticoid receptors (2,
12–14). No other neural volumes were extracted from the
FreeSurfer analysis to ensure that all analyses performed were
hypothesis driven.
Spectroscopy data were analyzed using the TARQUIN al-
gorithm version 4.3.7 to obtain concentrations for glutamate,
total N-acetylaspartate and N-acetylaspartylglutamate (NAA),
total choline (glycerophosphocholine and phosphocholine), total
creatine (creatinine and phosphocreatine), and glutamine plus
glutamate (Glx) (26). Because voxels tended to contain gray
matter, whitematter, andCSF in varying proportions, each voxel
was segmented and the metabolite concentrations corrected for
the differing water content (27).
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Statistical analysis
The current study was powered to detect a 20% difference
[standard deviation (SD) 0.36] in amygdala volume (power =
0.85, a = 0.05) between patients and controls (28). Because the
previous published neuroimaging study included only women
with CAH (28), and there is awell-described sexually dimorphic
pattern of brain development (29), all study recruits to the
current study were female.
Baseline characteristics of the two groups were compared
with unpaired Student t tests. Behavioral, quality of life (QOL),
and cognitive assessment scores were compared between pa-
tients with CAH and controls with analysis of covariance
corrected for education level. Correlations were performed to
assess the relationships of markers of androgen and glucocor-
ticoid exposure with psychometric assessment scores in patients
with CAH. Data were analyzed in SPSS version 22.
Total brain, CSF volume, and cerebral metabolite concen-
trations were compared between patients with CAH and con-
trols with analysis of covariance, with age as a covariate. For all
other neural volumes, total brain volume was an additional
covariate, and P values were adjusted to control for the false
discovery rate (FDR) (30).
Partial correlations were used to assess the relationship
between neural volumes and metabolite concentrations, when
initial results indicated that there was a significant difference in
neural volume and metabolite concentration between the two
groups, and neuropsychometric scores in patients with CAH,
with P values adjusted for FDR (30). For neural volumes,
correlations were also controlled for total brain volume. Cor-
relations were used to assess the relationship between markers
of androgen and glucocorticoid exposure, neural volumes, FA,
and mean diffusivity and metabolite concentrations (where
there was a significant difference in neural volume and me-
tabolite concentration between the two groups) only in patients
with CAH, adjusted for FDR (30). Variables examined were
those that showed a significant difference between patients with
CAH and controls in group analyses.
Results
Study cohort characteristics
Nineteen adult women (mean 30.6 years, range 18 to
49 years) with 21OHD receiving glucocorticoids (median
hydrocortisone dose 11.1 mg/m2 per day, range 10 to
13.8 mg/m2) and 19 healthy women (mean 32.8 years,
range 21 to 50 years) were recruited between July 2015 and
September 2016 (Table 1). All participants were right-
handed, had no abnormal neurologic findings, and had
completed mainstream schooling. All patients had 21OHD
confirmed by molecular genetic analysis. Genotype groups
null, A, B, and C contained 74%, 10.5%, 10.5%, and 5%
of the patients, respectively (18), which means that most
patients had a classic salt-wasting phenotype. One patient
hadnonclassicCAH.Medianage at diagnosiswith 21OHD
was 2 weeks (range birth to 17 years). Sixteen of the
19patientswithCAHalsohadmineralocorticoid deficiency
and were on fludrocortisone replacement (median dose
150mg) at the timeof assessment. Eight patientswere taking
prednisolone, and 11 were taking hydrocortisone; the
largest dose was taken in themorning in all patients. Fifteen
of 19 patients with CAH had been on the same gluco-
corticoid dose for $3 years. No patients with CAH were
taking the oral contraceptive pill.
One patient with CAH was unable to complete the
WAIS because of time constraints. One patient with CAH
Table 1. Age, Auxology, Educational Level, Glucocorticoid Dose, and Fasting Steroid Hormone
Concentrations
Patients With CAH Controls P
Number 19 19
Mean age, y (SD, SE) 30.6 (8.9, 2) 32.8 (8.5, 2) 0.4
Mean height, cm (SD, SE) 158.3 (8.3, 1.9) 164.9 (5.9, 1.4) 0.008a
Mean weight, kg (SD, SE) 77.1 (16.1, 3.7) 73.9 (17.8, 4.2) 0.57
Mean body mass index, kg/m2 (SD, SE) 30.9 (6.5, 1.5) 27.1 (6.1, 1.4) 0.08
Mean head circumference, cm (SD, SE) 55.2 (2.6, 0.6) 55.7 (2.1, 0.5) 0.6
Type 1 Chiari anomaly 4 0
Mean educational level (graded 1 to 6) (SD, SE) 4.3 (1.3, 0.3) 4.3 (1.2, 0.3) 0.9
Patients With CAH Only Median (Q1–Q3) Reference Range
Mineralocorticoid dose, mg/d 150 (100–237) N/A
Glucocorticoid equivalent dose, mg/m2/db 11.1 (10–13.8) N/A
Glucocorticoid equivalent dose, mg/d 20 (16–25) N/A
Plasma renin concentration 27 (13–48) 1.8–59.4 ng/L
Serum 17-hydroxyprogesterone 62 (2–168) 0.6–6 nmol/L
Serum dehydroepiandrosterone 0.54 (0.2–2.6) 2.68–9.23 nmol/L
Serum androstenedione 7.7 (3.2–15.3) 0.9–7.5 nmol/L
Serum testosterone 1.9 (0.8–2.9) ,1.9 nmol/L
Abbreviations: N/A, not applicable; SE, standard error.
aP values remain significant after we controlled for FDR (30).
bHydrocortisone dose; in patients taking prednisolone instead of hydrocortisone,we calculated the equivalent dose bymultiplying total prednisolone dose
by 4 (19).
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and one control did not tolerate the MRI scan but
completed all other study components. MRI data quality
was adequate in all subjects (V.S.). Temporal voxel MRS
spectra were deemed to be suitable for analysis in
17 patients with CAH and 16 controls, and parietal voxel
spectra were deemed to be suitable for analysis in
18 patients with CAH and 17 controls, as judged by visual
inspection by two independent observers (A.C.P., D.C.).
Psychometric assessment
The physical component of QOL was significantly
lower in patients with CAH than in controls (P , 0.001)
(Table 2). Patients with CAH scored higher on the de-
pression component of the HADS questionnaire; however,
no one scored in the clinical range (P = 0.02) (Table 2).
There was no significant difference in full-scale
IQ between patients with CAH and controls. When
compared with controls, patients with CAH had signif-
icantly lower working memory index (P = 0.04), pro-
cessing speed (P = 0.03), digit span (P = 0.04), and matrix
reasoning scores (P = 0.03) (Table 3).
CNS abnormalities in patients with CAH
Four of 19 patients with CAH (21%) had a type
1 Chiari anomaly; brain MRI was otherwise normal on
visual inspection in all subjects. In none of the study
participants was a pituitary gland abnormality reported;
however, specific pituitary views were not acquired.
Widespread reductions in FA were present in the su-
perior longitudinal fasciculus, inferior fronto-occipital
fasciculus, corticospinal tract, uncinated fasciculus, cin-
gulate gyrus, hippocampus, and corpus callosum in
patients with CAH (P , 0.05) (Fig. 1). Mean diffusivity
was increased bilaterally in the superior and inferior
longitudinal fasciculus, inferior fronto-occipital fascicu-
lus, anterior thalamic radiation, corticospinal tract, un-
cinate fasciculus, cingulate gyrus, and hippocampus in
patients with CAH (P , 0.05).
Although CSF volume was significantly higher in
patients with CAH (P = 0.003), total brain volume was
not significantly different between patients with CAH
and controls. After correction for multiple comparisons,
localized reductions in neural volumes were present in
patients with CAH in the right hippocampus, left and
right thalami, cerebellum, and brainstem (P = 0.028,
0.007, 0.008, 0.014, 0.03, respectively) (Table 4).
There were no significant differences in metabolite
concentrations between patients with CAH and controls
in the parietal voxel. In the mesial temporal voxel, total
choline and total creatine were significantly lower in
patients with CAH than controls (P = 0.001 and P = 0.04,
respectively) (Table 4). Only total choline remained sig-
nificantly lower after correction for multiple comparisons.
Correlations between MRI findings and cognitive
assessment scores in patients with CAH
There were significant correlations between cerebellar
volume and matrix reasoning scores (r = 0.7, P = 0.002;
Fig. 2A) and between brainstem volume, working mem-
ory performance, and digit span scores (r = 0.6, P = 0.009,
r = 0.59, P = 0.01, respectively; Fig. 2B and 2C).
Spectroscopy-acquired left mesial temporal lobe total
choline correlated significantly with working memory
index (r = 0.62, P = 0.01; Fig. 2D). There were no sig-
nificant relationships between FAandmeandiffusivity and
cognitive assessment scores.
Correlations between markers of glucocorticoid and
androgen exposure, MRI findings, and cognitive
assessment scores in patients with CAH
Increased glucocorticoid equivalent dose (mg) correlated
significantly with reduced working memory (r =20.52, P =
0.03) and digit span scores (r =20.51,P = 0.03) (Fig. 2E and
2F). Therewere no significant relationships betweenmarkers
of androgen exposure and psychometric assessment scores.
Table 2. HADS and World Health Organization QOL Scores in Patients With CAH and Controls Matched for
Age, Sex, and Educational Status
Patients With CAH Controls P
World Health Organization QOL questionnaire
Number of participants 19 19
QOL Physical 92 (80–108) 128 (116–132) 0.000001a
QOL Psychological 72 (60–96) 92 (88–100) 0.049
QOL Social Relationships 44 (36–52) 48 (40–52) 0.56
QOL Environment 116 (108–136) 124 (108–136) 0.37
QOL Total 90 (77–101) 108 (96–114) 0.001a
HADS questionnaire
HADS Anxiety 7 (5–11) 6 (4–8) 0.4
HADS Depression 5 (3–7) 2 (1–3) 0.02a
Data presented as median (Q1 to Q3).
aP values remain significant after we controlled for the FDR (30).
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Higher glucocorticoid-equivalent dose (mg) correlated
significantly with reduced mesial temporal lobe total
choline (r = 20.72, P = 0.001; Fig. 2G) and mean dif-
fusivity (r = 20.5, P = 0.03; Fig. 2H), suggesting that
patients exposed chronically to higher glucocorticoid
doses have greater reductions in mesial temporal lobe
total choline and white matter microstructure, reflected
by total choline concentration and mean diffusivity.
There were no significant differences in any of the cog-
nitive or MRI abnormalities identified between those
taking prednisolone and those prescribed hydrocorti-
sone. There were no significant associations between
markers of androgen exposure, MRI, and cognitive
findings.
Discussion
Using multiple quantitative imaging modalities in con-
junction with neuropsychological assessment enabled us
to identify functionally significant biomarkers of the
disease process (CAH) and treatment effects (steroid
exposure) in patients with CAH. Patients had global
abnormalities of cerebral white matter, with local-
ized reductions in neural volumes in regions of the brain
that have previously been documented to contain high
concentrations of androgen, mineralocorticoid, and glu-
cocorticoid receptors (2, 12–14). The mesial temporal
lobe was affected bilaterally, with significant reductions
in white matter microstructure, right hippocampal vol-
ume, and left mesial temporal lobe choline. Interestingly,
although markers of androgen exposure did not relate to
the identified CNS abnormalities, exposure to higher
glucocorticoid doses was associated with significantly
worse cognitive performance and abnormal mesial tem-
poral lobe total choline and white matter mean
diffusivity.
Concordant with finding of previous studies (17, 31),
we found reduced working memory and digit span scores
and impaired quality of life. Although we had a priori
hypotheses that working memory, processing speed, and
digit span would be reduced in patients with CAH based
on previous studies, these differences did not remain after
we controlled for multiple comparisons (17, 32). Cog-
nitive abnormalities in patients with CAH may relate to
the supraphysiological glucocorticoid doses used to
suppress adrenal androgen production (17). In support of
this hypothesis working memory, episodic and declarative
memory are adversely affected in patients treated with ex-
ogenous glucocorticoids, in adults with Cushing syndrome
producing excess endogenous glucocorticoids, and in healthy
Table 3. Cognitive Functional Assessment Scores in Patients With CAH and Controls Matched for Age, Sex,
and Educational Status
Patients With CAH Controls P
WAIS–Fourth Editiona
Number of participants 18 19
Full Scale IQ 94.5 (87–110) 110 (97–117) 0.09
Perceptual Reasoning Index 103.2 (92.5–119) 104 (98–115) 0.6
Verbal Comprehension Index 98.5 (82.5–110) 110 (87–112) 0.3
Working Memory Index 92 (76.2–105) 100 (100–114) 0.04b
Processing Speed Index 98.5 (89–113) 111 (102–120) 0.03b
Digit Span 7 (6–11) 10 (8–11) 0.04b
Arithmetic 9.5 (5.7–12.2) 11 (9–13) 0.1
Symbol Search 10.5 (8–12) 11 (10–13) 0.1
Coding 10 (7.8–12) 11 (10–15) 0.07
WMSa
Number of participants 19 19
Design 1 Scaled 9 (7–11) 11 (9–14) 0.02b
Design 2 Scaled 11 (9–12) 11 (10–16) 0.06
Visual Repetition Scaled 1 11 (8–13) 10 (8–12) 0.61
Visual Repetition Scaled 1 12 (9–15) 12 (10–14) 0.97
Content Scaled 1 10 (9–12) 12 (7–13) 0.4
Content Scaled 2 10 (8–12) 12 (10–15) 0.07
Spatial Scaled 1 10 (8–12) 12 (10–13) 0.13
Spatial Scaled 2 10 (9–13) 12 (9–15) 0.24
Auditory Memory Index 100 (93–113) 109 (94–118) 0.27
Visual Memory Index 105 (95–112) 110 (100–117) 0.22
Immediate Memory Index 102 (87–111) 109 (96–115) 0.16
Delayed Memory Index 104 (98–114) 115 (104–123) 0.14
aResults presented as median (Q1 to Q3) corrected for educational level.
bAlthoughwe had a priori hypotheses that working memory, processing speed, and digit span would be reduced in patients with CAH based on previous
studies, these results did not remain significant after correction for false discovery rate (17, 32, 34).
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human volunteers given glucocorticoids (33, 34). Our data
provide further evidence that cognitive abnormalities present
in patients with CAH relate to the degree of glucocorticoid
exposure, with patients on higher current glucocorticoid
doses having significantly worse performance on working
memory and digit span tests.
We identified an increased prevalence of type 1 Chiari
anomalies in patients with CAH, similar to a previous
study of adults with CAH in which 8 of the 39 patients
studied had type 1Chiari anomalies (4). Chiari anomalies
are a complex developmental disorder characterized by
primary axial skeletal defects and secondary neurologic
anomalies involving the craniocervical region (35). We
found the cerebellum and hindbrain to be smaller in
patients with CAH, suggesting that the downward dis-
placement of the cerebellar tonsils does not relate to brain
structural abnormalities. It is possible that in patients
with CAH, exposure to steroid hormone abnormalities
Figure 1. Association between CAH and FA (tract-based spatial statistics analysis comparing patients with CAH and healthy controls). Mean FA
skeleton overlaid on the mean FA map. Regions of the mean FA skeleton in green represent areas where there were no significant differences in
FA values in the patients with CAH and healthy controls. Areas in red and yellow are regions where the FA was significantly lower in the CAH
group and can be observed bilaterally in the superior longitudinal fasciculus, inferior fronto-occipital fasciculus, corticospinal tract, uncinate
fasciculus, cingulate gyrus, hippocampus, and corpus callosum (P , 0.05). FA is a dimensionless index.
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early in embryonic developmentmay affect occipital bone
formation antenatally (35). The relevance of this in-
creased prevalence of type 1 Chiari anomalies to the
clinical course and ongoing management in patients with
CAH remains to be elucidated.
Patients with CAH are exposed to multiple potentially
pathological hormone abnormalities, and the neural
changes we describe are likely to be multifactorial. Hy-
poglycemia and salt loss at initial presentation and
subsequently at the time of adrenal crisis are likely to
affect brain structure. We were unable to examine the
difference in CNS changes between patients with and
withoutmineralocorticoid deficiency because of the small
number of patients without salt loss recruited to the
study. However, we identified no reduction in full-scale
IQ in our patients with CAH, in contrast to previous
studies that report reduced full-scale IQ in patients with a
history of salt wasting crises necessitating inpatient
hospital management (36). Future studies should aim to
dissect the impact of salt wasting on the CNS by including
patients with conditions such as isolated aldosterone
synthase deficiency.
Gross structural brain white matter abnormalities
have been described previously in patients with CAH, in
conjunction with thinning of the corpus callosum and
small volume hippocampi (4, 37). However, we have
identified widespread abnormalities in white matter
microstructure in patients with CAH. Because longitu-
dinal DTI studies report corpus callosum FA to be higher
in men than in women, our findings with regard to white
matter microstructure are unlikely to be caused by excess
androgen exposure (38). Animal and human disease
models provide some evidence that the abnormalities we
describe relate to glucocorticoid treatment in patients
with CAH. In animal models prolonged exposure to
raised glucocorticoid concentrations leads to the in-
hibition of oligodendrocyte precursor proliferation, re-
ducing myelin production (39). Patients with Cushing
disease have significant reductions in FA and increases in
mean diffusivity throughout the brain (40). Importantly,
partial resolution of neuritic degenerative changes in
rodents, significant improvements in cognitive function,
and reversal of cerebral atrophy in humans occur after
withdrawal of glucocorticoids, suggesting that modifi-
cation of treatment regimens in patients with CAH may
improve myelination and cognitive function (41).
In contrast to the expected finding of increased
amygdala volume in girls with CAH exposed to excess
androgens antenatally, Merke et al. (28) identified
smaller amygdala volumes by using a manual tracing
Table 4. Neural Volumes Determined From T1-Weighted MRI and FreeSurfer
Patients With CAH Controls P
Number of participants 18 18
Total brain volume (interquartile range) 1044732 (115246) 1069078 (86972) 0.47
CSF 1013 (914–1302) 839 (750–918) 0.003a
Left hippocampus 3792 (3611–4054) 4014 (3644–4271) 0.16
Right hippocampus 3744 (3639–3969) 3981 (3682–4272) 0.028a
Left amygdala 1509 (1406–1685) 1658 (1492–1848) 0.055
Right amygdala 1680 (1524–1785) 1718 (1488–1958) 0.6
Left thalamus 6318 (5894–6874) 6906 (6262–7578) 0.007a
Right thalamus 6240 (5689–6730) 6622 (6333–7079) 0.008a
Cerebellum (SD, SE) 113878 (106656–125254) 127499 (11484–134100) 0.014a
Brainstem 19145 (17569–20910) 20527 (19863–21794) 0.03a
Mesial temporal voxel metabolites
Number of participants 17 16
Glutamate 7.9 (6.2–10.3) 8 (4.9–10.8) 0.6
Total NAA 5.6 (4.6–6.3) 6.1 (4.9–7.2) 0.1
Total choline 1.9 (1.5–2.1) 2.3 (2–2.5) 0.001a
Total creatine 6.8 (5.8–7.9) 8 (7.6–8.9) 0.04
Glx 14.6 (11.2–18.3) 15 (11–16.9) 0.7
Parietal voxel metabolites
Number of participants 18 17
Glutamate 3.7 (2.9–4.4) 3.6 (2.4–4.5) 0.8
Total NAA 7.7 (7.2–8.8) 7.6 (7.3–8.6) 0.6
Total choline 2 (1.6–2.2) 1.9 (1.7–2) 0.5
Total creatine 6.4 (5.8–6.7) 6.1 (5.8–6.6) 0.6
Glx 4.5 (3.1–7.2) 6.1 (3–8.4) 0.7
Data presented as median (Q1 to Q3). Results corrected for age at scan and total brain volume (25) and spectroscopy-acquired CNS metabolite
concentrations; data analyzed with TARQUIN (26).
Abbreviation: SE, standard error.
aP values remains significant after we controlled for the FDR (30).
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Figure 2. Associations between cognitive function scores and neural volumes, hydrocortisone equivalent dose, cognitive function scores, mesial
temporal lobe total choline, and mean diffusivity in adults with CAH. Partial correlations were used to assess the relationship between neural
volumes and metabolite concentrations and neuropsychometric test results for WAIS and WMS assessments in patients with CAH. For neural
volumes, correlations were also controlled for total brain volume. Correlations were used to assess the relationship between markers of androgen
and glucocorticoid exposure, neural volumes, fractional anisotropy, and mean diffusivity and metabolite concentrations, in patients with CAH. All
P values were adjusted to control for the FDR (30). There were significant correlations between (A) cerebellar volume and matrix reasoning scores
(r 5 0.7, P 5 0.002) and (B and C) brainstem volume, working memory performance, and digit span scores (r 5 0.6, P 5 0.009, r 5 0.59, P 5
0.01, respectively). (D) Spectroscopy-acquired left hippocampus total choline correlated significantly with working memory index in patients with
CAH (r 5 0.62, P 5 0.01). (E and F) Increased glucocorticoid equivalent dose (mg) correlated significantly with reduced working memory
(r 5 20.52, P 5 0.03) and digit span (r 5 20.51, P 5 0.03) scores. Higher glucocorticoid equivalent dose (mg) correlated significantly with (G)
reduced mesial temporal lobe total choline (r 5 20.72, P 5 0.001) and (H) mean diffusivity (r 5 20.5, P 5 0.03).
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method with volumetric MRI acquisition on a 1.5-T
scanner. This finding was interpreted as an effect of
postnatal excess glucocorticoid exposure in patients with
CAH. Although we did not replicate this result, our
findings of localized volume loss in the right hippo-
campus, the left and right thalami, the cerebellum, and
the brainstem also differs from the pattern of larger
limbic, insula, and occipital lobe volumes and the smaller
parietal lobe and opercular left inferior frontal gyrus
volumes seen in association with increased testosterone
exposure (1, 13, 16, 36, 42).
Mineralocorticoid receptors, which have a similar
affinity for cortisol and aldosterone, are located in limbic
structures, particularly in the hippocampus, but are al-
most absent elsewhere in the brain (14). Neurons in the
hippocampus do not express 11b-hydroxysteroid de-
hydrogenase type 2,which elsewhere in the body converts
corticosterone and cortisol into inactive metabolites.
Therefore, in the hippocampus, the mineralocorticoid
receptor is considered mainly to be a glucocorticoid-
activated receptor, making the hippocampus selectively
vulnerable to nonphysiological fluctuations in gluco-
corticoid concentrations (14). Glucocorticoids increase
excitatory amino acids and serotonin concentrations,
leading to neural damage (33), and may also increase the
vulnerability of neurons to other insults, such as ischemia,
via reduced neuronal glucose uptake (43). Administra-
tion of oral hydrocortisone in humans leads to reduced
hippocampalmetabolism (44), and patientswith Cushing
syndrome, exposed chronically to high glucocorticoid
concentrations, have localized volume loss in the hip-
pocampus and temporal lobes (41). The cerebellum,
which we found to be significantly smaller in patients
with CAH, has the highest concentration of CNS glu-
cocorticoid receptors (12), with exogenous glucocorti-
coids reducing cerebellum growth in mice (45). Although
the current study design does not enable us to determine
the exact etiology of the structural impairments identi-
fied, the reductions in neural volumes in regions of the
brain with high concentrations of glucocorticoid re-
ceptors, in areas shown to be affected negatively by in-
creased glucocorticoid exposure in in vivo and murine
studies, suggests that the brain abnormalities we describe
in patients with CAH relate to chronic excess gluco-
corticoid exposure. These findings require replication in
larger, independent samples.
We identified a reduction in total choline, a marker of
CNS myelination, inflammation, and membrane syn-
thesis and repair in patients with CAH, which did not
extend to the right parietal lobe. Exposure to higher
glucocorticoid doses was significantly associated with
mesial temporal lobe total choline. This finding suggests
that reduction in total choline in the hippocampal voxel
relates to raised glucocorticoid concentrations in patients
withCAHbecause themesial temporal lobe contains high
concentrations of glucocorticoid receptors (2). Khiat et al.
(15) identified a reduction in choline resonance in 13
patients with Cushing syndrome in frontal and thalamic
areas, hypothesized to reflect an inhibition of phospho-
lipase A2 activity by glucocorticoids; phospholipase A2
hydrolyzes specific ester bonds in membrane phospho-
lipids (46). Importantly, after normalization of cortisol
concentrations, improvements in memory and the brain
metabolite profile were documented (15).
Conclusion
CAH has a profound impact on normal brain and cog-
nitive development, with the effects we describe most
marked in the mesial temporal lobe. We also describe a
significant association between current glucocorticoid
replacement regimens and cognitive and CNS abnor-
malities. Although we are not able to control for previous
episodes of hypoglycemia and salt loss at initial pre-
sentation and subsequently during adrenal crisis in-
cidents, the recent development of more physiological
glucocorticoid replacement regimens and other modali-
ties that offer improved control of altered steroidogenesis
in CAH (3) may provide opportunities to use the bio-
markers identified in the current study (mean diffusivity,
mesial temporal lobe total choline) to assess the impact
treatments on the CNS in patients with CAH. These
findings are also relevant to the wider population, of
whom 1% are on long-term glucocorticoid therapy (47).
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